Corcept Therapeutics stock plunges after FDA rejects hypercortisolism drug

Key Concepts

• Options Puts: Contracts giving the buyer the right, but not the obligation, to sell an asset at a specified price on or before a certain date. Profitable when the asset price declines.
• FDA (Food and Drug Administration): U.S. agency responsible for regulating food, drugs, and medical devices. Their assessment of risk/benefit is crucial for pharmaceutical companies.
• Pipeline (Pharmaceutical): The collection of drug candidates a pharmaceutical company is developing. A "deep pipeline" indicates numerous potential future products.
• Short Interest: The percentage of a company’s shares that have been sold short by investors who believe the price will decline. “Short covering” occurs when short sellers buy back shares to close their positions, potentially driving up the price.
• Balance Sheet: A financial statement that reports a company’s assets, liabilities and equity at a specific point in time. A “solid balance sheet” indicates financial stability.

---

Unusual Option Activity & Stock Decline of CORT

The discussion centers around the significant stock decline of CORT, a pharmaceutical company. Unusual option activity, specifically the purchase of put options, preceded and correctly predicted this downturn. This activity was first observed in October, and proved prescient as the stock price plummeted from approximately $70 to as low as $35 (and potentially even below $35 at the time of discussion). Prior to this drop, the stock had reached a high of $83. The current price is around $34, representing a roughly 50% decrease from its recent peak.

FDA Concerns as a Catalyst

The primary catalyst for the stock’s dramatic fall was a negative assessment from the FDA. The FDA questioned whether the benefits of CORT’s drug outweighed the associated risks. This assessment significantly impacted investor confidence and triggered the sell-off. The speaker emphasizes that this FDA decision was the key factor that “threw people off.”

Potential for Future Opportunity

Despite the substantial decline, the speakers identify potential for future investment in CORT. They highlight the company’s “deep pipeline” of other drug candidates, suggesting that the current price may present a buying opportunity once the stock stabilizes. The speaker states, “Now, this is a company that has a deep pipeline. I really like that.” They caution against attempting to “buy the bottom” and instead advocate for waiting to see a positive trend reversal before investing.

Financial Health & Short Covering

A key differentiating factor for CORT, compared to many other therapeutic companies, is its “solid balance sheet.” The speaker notes that many therapeutic companies have precarious financial positions, but CORT’s balance sheet is not “upside down.” Furthermore, the stock has a significant short interest, estimated at 10-12%. The speakers anticipate that as short sellers begin to “cover” their positions (buy back shares), this will create upward pressure on the stock price, presenting a favorable entry point for investors. The speaker believes “that’s the time to jump in.”

Logical Flow & Interconnections

The conversation logically progresses from observing the unusual option activity, to identifying the cause of the stock decline (FDA concerns), to assessing the company’s underlying strengths (pipeline and balance sheet), and finally, to outlining a potential investment strategy based on anticipated short covering. The discussion connects the predictive power of options trading with the fundamental factors influencing a pharmaceutical company’s stock performance.

Notable Quote

“Unfortunately for them, they met the end points. That part is good. But then all of a sudden, the FDA came in and they were like, well, you know, the the benefits, are they worth it for the risk?” – This quote encapsulates the unexpected turn of events that led to the stock’s downfall, despite initial positive results.